Summary of Key Points
The 150-year-old American pharmaceutical company Eli Lilly has seen its market value soar past $1.21 trillion thanks to a “super drug” called tirzepatide, which combines the functions of Mounjaro (for diabetes) and Zepbound (for weight loss). This has made it the most valuable pharmaceutical company in human history, surpassing the combined value of Johnson & Johnson and AbbVie. This success is not accidental:
1. Obesity has evolved from a “lifestyle issue” to a chronic disease defined by the WHO, opening up a trillion-dollar market for long-term medication.
2. Eli Lilly has bypassed the traditional pharmaceutical industry’s “patent cliff” through product iteration (from injectable to oral to multi-target drugs).
3. The company invested $50 billion in expanding its production capacity to create a competitive barrier.
4. The capital market has redefined the value of pharmaceutical companies, emphasizing platform-based growth similar to that of technology firms, rather than relying on a single blockbuster product.
However, high valuations also come with risks, such as potential price cuts by health insurance providers and long-term safety concerns. Meanwhile, Chinese pharmaceutical companies are seeking to align themselves with global standards through international licensing agreements.
1. One Drug Supports the Majority of the Company’s Revenue: The “Identity Transformation” of the Obesity Market is Crucial
Eli Lilly’s core product, tirzepatide, serves two purposes: treating diabetes with Mounjaro and obesity with Zepbound. In the second quarter of 2026, these two drugs generated $14.87 billion in sales, accounting for 64.7% of the company’s total revenue—meaning that a significant portion of Eli Lilly’s earnings comes from this single product.
Why is tirzepatide so popular? The obesity market has changed dramatically. Previously, obesity was seen as a matter of poor diet and exercise; now, it is recognized by the WHO as a chronic, recurring disease, requiring long-term medication that may be covered by health insurance. With 2.5 billion people worldwide being overweight and 890 million obese, the market has expanded from tens of billions to hundreds of billions of dollars (Reuters predicts the US weight loss drug market will exceed $100 billion by 2030). Eli Lilly’s valuation reflects this anticipated shift in consumer behavior.
2. Bypassing the “Patent Cliff”: Turning Drugs into “Iterative Technology Products”
Traditional pharmaceutical companies fear the “patent cliff”—where sales plummet when a drug’s patent expires and generic versions become available. Eli Lilly’s strategy is to transform its products into a platform that can be continuously upgraded, similar to smartphones:
- First Generation: Injectable versions of Zepbound and Mounjaro, which proved their efficacy.
- Second Generation: The oral version, Foundayo, eliminating the need for injections and making the medication more accessible.
- Third Generation: The multi-target drug retatrutide, which has shown a 30% greater weight loss effect compared to the previous versions.
Eli Lilly is also expanding the indications for its drugs; for example, Zepbound is now used to treat both obesity and sleep apnea. This ensures that even when older drugs’ patents expire, new products will continue to generate revenue, meeting the capital market’s preference for “technology platform” models.
3. Investing $50 Billion in Capacity Expansion: The GLP-1 Race is a Competition in Manufacturing
GLP-1 drugs (such as Eli Lilly’s tirzepatide and Novo Nordisk’s Wegovy) require sophisticated production facilities, including specialized raw materials, purification systems, and packaging lines, as well as regulatory approvals. Novo Nordisk initially faced capacity constraints, which allowed Eli Lilly to gain a competitive advantage.
Since 2020, Eli Lilly has invested $50 billion in building new manufacturing facilities, such as a raw material plant in Indiana that will be operational by 2027, and another $4.5 billion in oral and multi-target drug production. This investment is not just about adding more production lines but also about rebuilding the industrial infrastructure for metabolic drugs. Investors now consider a company’s capacity as an important factor in its value.
4. The Hidden Risks of High Valuations: Six Prerequisites Must Be Met
Eli Lilly’s $1.21 trillion market value is based on six key assumptions:
- Patients Will Use the Drug Long-Term: If patients stop using it after a few years, revenue will decline.
- Health Insurance Will Cover the Cost: If insurance does not cover the medication, it will be unaffordable for many patients (for example, Zepbind costs $1,300 per month in the US).
- Price Cuts Can Be Offset by Sales: Eli Lilly has acknowledged that price cuts are necessary to maintain sales.
- The Next Generation of Drugs Will Be Successful: If clinical trials for retatrutide fail, the company’s growth strategy will be compromised.
- Long-Term Safety Is Not an Issue: There must be no serious side effects, such as liver or kidney damage or muscle loss.
- Competition Won’t Erode Profits: Competitors like Novo Nordisk and Pfizer are pursuing similar drugs, potentially squeezing profit margins.
The most critical factor is the ability to sustain these costs over the long term. If millions of people need to take these drugs for years, health insurance systems and governments must be able to afford the expense. This represents a major constraint on Eli Lilly’s valuation.
5. Opportunities for Chinese Pharmaceutical Companies: From “Imitation” to “Global Sales”
Eli Lilly’s success shows that Chinese companies can achieve global success through original research and development and international commercialization:
- Increasing Licensing: In the first half of 2026, Chinese pharmaceutical companies licensed 81 products for a total of approximately $11 billion (for example, Fosun Pharma licensing three drugs to Swiss company Sandoz).
- Rising Importance of Innovative Drugs: The revenue from innovative drugs at Hengrui Medicine has reached 63%, exceeding that of generic drugs.
However, there is still a significant gap: the total market value of China’s top ten pharmaceutical companies is only $264.7 billion, less than one-fourth of Eli Lilly’s. To become global giants, Chinese companies need to combine original research, global clinical trials, advanced production capabilities, and international sales.
Eli Lilly’s $1.21 trillion market value demonstrates that the potential value of pharmaceutical companies can be extremely high if they can capture large chronic disease markets, continuously innovate products, and build strong manufacturing foundations. This serves as both a model and a challenge for Chinese pharmaceutical companies to follow.